Health
Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT in High-Grade Gliomas®
Curasight A/S ("Curasight" or "the Company" – TICKER: CURAS), a clinical-stage radiopharmaceutical company developing first-in-class drug candidate uTREAT® targeting uPAR (urokinase-type plasminogen activator receptor), the functional driver of invasion, angiogenesis, and metastasis across most solid tumors, today announced encouraging preliminary data from the first patient dosed in ongoing Phase 1 clinical trial in patients with high-grade gliomas.
About this update from Curasight A/s
[{"type":"list","items":[{"val":[{"type":"text","content":"Clear uptake of uTREAT® in aggressive brain cancer (glioblastoma)","length":65,"tagName":"p"}]},{"val":[{"type":"text","content":"Early data support the potential of first-in-class uPAR-targeted theranostic approach to enable more specific diagnosis and more targeted treatment of high-grade gliomas and other uPAR expressing aggressive solid tumors","length":219,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":284,"olType":false},{"type":"text","content":"COPENHAGEN, Denmark, Jan. 12, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company" – TICKER: CURAS), a clinical-stage radiopharmaceutical company developing first-in-class drug candidate uTREAT® targeting uPAR (urokinase-type plasminogen activator receptor), the functional driver of invasion, angiogenesis, and metastasis across most solid tumors, today announced encouraging preliminary data from the first patient dosed in ongoing Phase 1 clinical trial in patients with high-grade gliomas.","length":525,"tagName":"p"},{"type":"text","content":"Position emission tomography (PET)-images from the first treated patient showed clear and sustained uptake of uTREAT® in the tumor, confirming that the drug successfully targets cancer tissue. The signal remained visible for at least 24 hours, indicating prolonged tumor binding and supporting the potential for effective radiation delivery to the tumor. The patient's PET signal persisted until the last PET scan (24 hours), demonstrating that uTREAT® has protracted binding kinetics, translating to a maximized tumor absorbed dose.","length":537,"tagName":"p"},{"type":"text","content":"These early results provide support for Curasight's uPAR-targeted approach in radiopharmaceuticals and the potential of uTREAT® as a novel therapy for patients with high-grade gliomas and other uPAR expressing aggressive solid tumors (>85% of solid tumors).","length":264,"tagName":"p"},{"type":"text","content":"The preliminary dosimetry readout of uTREAT® was in line with expectations and supports to continue with additional GBM patients. Currently more patients are enrolled, and top-line data is expected in Q2 2026.","length":209,"tagName":"p"},{"type":"text","content":""This first-patient data represents an important early milestone for Curasight and uTREAT®," says...